Check What Authors Claimed

 Quick Explanation Copied

 Long Explanation

Scientific Profile of Ugo Cavallaro

The available evidence centers on Cavallaro's 2011 EMBO Molecular Medicine study establishing NCAM as a pro-metastatic adhesion molecule in epithelial ovarian cancer (EOC) acting through FGFR signaling NCAM-FGFR clinical cohort data.

Methodological Strength

The study shows a hallmark of strong translational science: a large retrospective clinical cohort (252 primary tumors, 206 metastases, 20 normal controls) with grade/stage-stratified correlation (0/12 G1 vs 41/168 G3 NCAM-positive), an independent microarray validation (Crijns et al., 255 EOC samples), mechanistic dissection using knockdown, rescue, a signaling-defective DFN2 NCAM mutant, pharmacological (PD173074) and antibody (123C3) perturbation, and two in vivo models (orthotopic bursa and intraperitoneal dissemination) with 6–10 mice/group and therapeutic antibody testing at 10 mg/kg twice weekly NCAM-DFN2 and antibody blocking experiments. Declared funding was from public/charitable sources (AIRC, AICR, Cariplo, Italian Ministry of Health) with reagents from Pfizer; no competing financial interests were declared Funding and COI statement.

Blindspots and Uncertainty

Reported limitations include immunodeficient mouse models lacking tumor-immune interactions, retrospective TMA sampling, FGFR1-only subset staining (77 tumors), and possible off-target inhibitor effects; clinical correlation does not establish prognosis independently Study limitations section. OpenAlex metrics could not be retrieved (timeout), so citation impact cannot be quantified here.

 BGPT Author Review

Scientific Quality

Based on one deeply characterized paper, Cavallaro demonstrates strong translational design: large clinical TMA cohort, independent dataset validation, genetic and pharmacological controls, and two in vivo models. Limitations: single-author-record evidence, no survival endpoint data extracted, murine-only therapeutic validation. Cannot assess full career breadth without complete bibliometrics (OpenAlex timed out).

Communication Quality

Findings are presented with clear clinical framing (NCAM as therapeutic target) and layered evidence from patients to mice, making the work accessible to both basic and clinical audiences. The dense multi-model design may reduce readability for non-specialists.

Author Novelty

Repositioning NCAM from neural biology into ovarian cancer metastasis via a defined FGFR interaction was a fresh mechanistic insight in 2011, with a cell-surface target (123C3 antibody) offering a druggable angle. Not paradigm-shifting, but a genuinely novel axis.

Scientific Rigor

Rigorous use of loss-of-function, rescue with a signaling-deficient mutant, orthogonal inhibitor/antibody confirmation, independent expression dataset, and appropriate in vivo models. Deductions for retrospective sampling, small FGFR1 subset, lack of immune-competent models, and no blinding reported.